STOCK TITAN

Mirum officer plans sale of 658 restricted shares

An officer associated with Mirum Pharmaceuticals, Inc. files a Rule 144 notice to sell 658 restricted shares and discloses over 46,000 shares sold in the prior three months.

(Neutral)
(Neutral)
Form Type
144

Rhea-AI Filing Summary

Mirum Pharmaceuticals, Inc. (MIRM) is the issuer in a Rule 144 notice covering proposed sales of its common stock for the account of officer Jolanda Marie Howe. The planned sale involves 658 shares of common stock through a broker, Morgan Stanley Smith Barney LLC Executive Financial Services, with a stated dollar amount of $65,800.00 as of September 2, 2026.

The shares to be sold are identified as restricted stock acquired from the issuer on January 23, 2026. The notice also lists prior sales by Jolanda Marie Howe over the preceding three months, including 40,000 shares for $4,000,000.00 on August 18, 2026 and several smaller transactions in June, July, and early August 2026.

Positive

  • None.

Negative

  • None.
Shares proposed for sale 658 shares Common stock under Rule 144 notice for Jolanda Marie Howe
Stated dollar amount for proposed sale $65,800.00 Corresponding to 658 shares with broker Morgan Stanley Smith Barney LLC Executive Financial Services as of September 2, 2026
Largest recent sale 40,000 shares for $4,000,000.00 Sale of Mirum common stock by Jolanda Marie Howe on August 18, 2026
Other recent sale on August 3, 2026 1,840 shares for $193,733.60 Mirum common stock sold by Jolanda Marie Howe
Sale on July 1, 2026 2,721 shares for $326,520.00 Mirum common stock sold by Jolanda Marie Howe
Sale on June 17, 2026 2,594 shares for $264,458.30 Mirum common stock sold by Jolanda Marie Howe
Rule 144 regulatory
"See the definition of "person" in paragraph (a) of Rule 144."
Rule 144 is a U.S. securities regulation that sets conditions under which restricted or insider-held shares can be legally resold to the public, such as required holding periods, availability of public information, limits on how much can be sold at once, and certain filing requirements. For investors it matters because it determines when previously locked-up shares can enter the market — like a release valve that can increase supply, affect share price, and signal insider intent.
Restricted Stock financial
"Common | 01/23/2026 | Restricted Stock | ISSUER"
Shares granted to an individual that carry limits on transfer or sale until certain conditions are met, such as staying with the company for a set time or hitting performance targets. Think of them as a locked gift that gradually opens; for investors they matter because they affect how many shares may enter the market later, signal management incentives and potential dilution, and reveal confidence in future company performance.
issuer regulatory
"Restricted Stock | ISSUER | | | 658 | 01/23/2026"

FAQ

What does the Form 144 filing disclose for Mirum Pharmaceuticals, Inc. (MIRM)?

It discloses a planned sale under Rule 144 of 658 shares of Mirum Pharmaceuticals, Inc. common stock for the account of officer Jolanda Marie Howe, along with details of her recent sales of Mirum common stock during the past three months.

How many Mirum Pharmaceuticals (MIRM) shares are proposed to be sold and through which broker?

The notice covers a proposed sale of 658 shares of Mirum Pharmaceuticals common stock through Morgan Stanley Smith Barney LLC Executive Financial Services, with the trading venue identified as NASDAQ and a stated dollar amount of $65,800.00 on September 2, 2026.

What type of Mirum Pharmaceuticals (MIRM) shares are being sold by Jolanda Marie Howe?

The securities to be sold are Mirum Pharmaceuticals common stock classified as Restricted Stock, acquired from the issuer on January 23, 2026. The filing ties the 658 shares proposed for sale to this restricted stock acquisition.

What Mirum Pharmaceuticals (MIRM) stock sales has Jolanda Marie Howe made in the past three months?

The notice lists four sales of Mirum common stock: 40,000 shares for $4,000,000.00 on August 18, 2026; 1,840 shares for $193,733.60 on August 3, 2026; 2,721 shares for $326,520.00 on July 1, 2026; and 2,594 shares for $264,458.30 on June 17, 2026.

Who is the person selling Mirum Pharmaceuticals (MIRM) shares in this Form 144?

The selling person is Jolanda Marie Howe, identified in the filing as an Officer of Mirum Pharmaceuticals, Inc. The notice provides her name and address and aggregates her sales that are subject to Rule 144 requirements.

What dates are associated with the Mirum Pharmaceuticals (MIRM) restricted stock being sold?

The restricted Mirum Pharmaceuticals common stock to be sold is shown as acquired on January 23, 2026, with 658 shares listed in the securities-to-be-sold section and a related date of January 23, 2026 noted again in that section.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
Learn about SEC filing dates

144: Filer Information

144: Issuer Information

144: Securities Information



Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold


* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.



Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

144: Remarks and Signature